Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNH-118110 in Advanced Solid Tumors
NCT07649200Phase 1Not yet recruiting
- Sponsor
- ScinnoHub Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNH-118110 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by ScinnoHub Pharmaceutical. Primary endpoints: Safety evaluation and Maximum tolerated dose or maximum administered dose. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
SNH-118110
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07649200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649200.